Patients’ baseline characteristics based on their county of residence
| Total | Metropolitan | Rural | Urban | p-value | |
| Total | 111 627 | 94 290 | 1951 | 15 386 | |
| Age (mean) | 62.7 | 62.5 | 64 | 63.2 | <0.001 |
| Race | |||||
| White | 96 697 (86.6%) | 80 658 (85.5%) | 1801 (92.3%) | 14 238 (92.5%) | |
| American Indian | 408 (0.4%) | 261 (0.3%) | 27 (1.4%) | 120 (0.78%) | <0.001 |
| Asian | 3418 (3.1%) | 3314 (3.5%) | 4 (0.2%) | 100 (0.65%) | <0.001 |
| Black | 8853 (7.9%) | 8026 (8.5%) | 105 (5.4%) | 722 (4.7%) | <0.001 |
| Pacific | 213 (0.2%) | 189 (0.2%) | 1 (0.01%) | 23 (0.16%) | 0.04 |
| Unknown | 2038 (1.8%) | 1842 (2.0%) | 13 (0.7%) | 183 (1.2%) | |
| Spanish | |||||
| Non-Spanish | 99 475 (89.1%) | 83 615 (88.7%) | 1775 (91.0%) | 14 085 (91.5%) | |
| Spanish | 6271 (5.6%) | 5941 (6.3%) | 25 (1.3%) | 305 (2.0%) | <0.001 |
| Unknown | 5881 (5.3%) | 4734 (5.0%) | 151 (7.7%) | 996 (6.5%) | |
| Insurance | |||||
| Medicare | 47 010 (43%) | 38 721 (41.1%) | 968 (49.6%) | 7321 (47.6%) | |
| Medicaid | 6785 (6.2%) | 5672 (6.0%) | 110 (5.6%) | 1003 (6.5%) | 0.01 |
| Not insured | 4503 (4.1%) | 3722 (3.95%) | 100 (5.1%) | 681 (4.4%) | 0.63 |
| Other government | 1041 (1%) | 843 (0.9%) | 20 (1.0%) | 178 (1.15%) | 0.25 |
| Private | 49 912 (45.7%) | 43 365 (45.9%) | 708 (36.3%) | 5839 (37.9%) | <0.001 |
| Insurance status unknown | 2376 (2.2%) | 1967 (2.1%) | 45 (2.3%) | 364 (2.4%) | 0.60 |
| Income ($) | |||||
| <38 000 | 17 405 (15.6%) | 11 771 (12.5%) | 788 (40.4%) | 4846 (31.5%) | <0.001 |
| 38 000–47 999 | 25 369 (22.7%) | 18 159 (19.3%) | 743 (38.1%) | 6467 (42.0%) | <0.001 |
| 48 000–62 999 | 30 105 (27%) | 26 445 (28.0%) | 351 (18.0%) | 3309 (21.5%) | <0.001 |
| ≥63 000 | 38 548 (34.5%) | 37 764 (40.1%) | 58 (3.0%) | 726 (4.7%) | |
| Unknown | 200 (0.2%) | 151 (0.2%) | 11 (0.6%) | 38 (0.2%) | |
| High school education (%) | |||||
| <7.0 | 28 828 (25.8%) | 27 262 (28.9%) | 200 (10.3%) | 1366 (8.9%) | |
| 7.0–12.9 | 37 225 (33.3%) | 31 978 (33.9%) | 531 (27.2%) | 4716 (30.7%) | <0.001 |
| 13.0–20.9 | 27 835 (24.9%) | 21 507 (22.8%) | 633 (32.4%) | 5695 (37.0%) | <0.001 |
| ≥21 | 17 590 (15.8%) | 13 433 (14.2%) | 578 (29.6%) | 3579 (23.3%) | <0.001 |
| Unknown | 149 (0.1%) | 110 (0.1%) | 9 (0.5%) | 30 (0.2%) | |
| Mean distance to care center (miles | 35 | 27.4 | 88.4 | 72.9 | <0.001 |
| Charlson score | 2.22 | 2.22 | 2.24 | 2.25 | <0.001 |
| Year of diagnosis | 0.004 | ||||
| 2004 | 5915 (5.3%) | 4992 (5.3%) | 108 (5.5%) | 815 (5.3%) | |
| 2005 | 6369 (5.7%) | 5375 (5.7%) | 103 (5.3%) | 891 (5.8%) | |
| 2006 | 6663 (6.0%) | 5529 (5.9%) | 112 (5.7%) | 1022 (6.6%) | |
| 2007 | 7385 (6.6%) | 6267 (6.6%) | 139 (7.1%) | 979 (6.4%) | |
| 2008 | 7910 (7.1%) | 6613 (7.0%) | 158 (8.1%) | 1139 (7.4%) | |
| 2009 | 8162 (7.3%) | 6924 (7.3%) | 158 (8.1%) | 1080 (7.0%) | |
| 2010 | 8336 (7.5%) | 7045 (7.5%) | 164 (8.4%) | 1127 (7.3%) | |
| 2011 | 8951 (8.0%) | 7528 (8.0%) | 153 (7.8%) | 1270 (8.3%) | |
| 2012 | 9430 (8.4%) | 7980 (8.5%) | 148 (7.6%) | 1302 (8.5%) | |
| 2013 | 10 340 (9.3%) | 8698 (9.2%) | 189 (9.7%) | 1453 (9.4%) | |
| 2014 | 10 627 (9.5%) | 8969 (9.5%) | 170 (8.7%) | 1488 (9.7%) | |
| 2015 | 11 154 (10.0%) | 9538 (10.1%) | 180 (9.2%) | 1436 (9.3%) | |
| 2016 | 10 385 (9.3%) | 8832 (9.4%) | 169 (8.7%) | 1384 (9.0%) | |
| Grade | 0.03 | ||||
| high | 69 084 (61.9%) | 58 132 (61.7%) | 1203 (61.7%) | 9749 (63.4%) | |
| low | 11 028 (9.9%) | 9370 (9.9%) | 175 (9.0%) | 1483 (9.6%) | |
| unknown | 31 515 (28.2%) | 26 788 (28.4%) | 573 (29.4%) | 4154 (27.0%) | |
| FIGO stage | |||||
| Stage I | 24 327 (21.8%) | 20 667 (21.9%) | 417 (21.4%) | 3243 (21.1%) | |
| Stage II | 9965 (8.9%) | 8475 (9.0%) | 162 (8.3%) | 1328 (8.6%) | 0.83 |
| Stage III | 42 032 (37.7%) | 35 155 (37.3%) | 735 (37.7%) | 6142 (39.9%) | <0.001 |
| Stage IV | 26 889 (24.1%) | 22 855 (24.2%) | 488 (25.0%) | 3546 (23.0%) | 0.89 |
| Unknown | 8414 (7.5%) | 7138 (7.6%) | 149 (7.6%) | 1127 (7.3%) | |
| Days to treatment (mean) | 11.3 | 11.3 | 10.9 | 11 | 0.14 |
| Days to surgery (mean) | 28.4 | 28.3 | 28.3 | 29.9 | 0.27 |
| Residual disease after surgery | |||||
| R0 | 47 667 (42.7%) | 40 383 (42.8%) | 769 (39.4%) | 6515 (42.3%) | <0.001 |
| R1 | 31 984 (28.7%) | 26 654 (28.3%) | 640 (32.8%) | 4690 (30.5%) | |
| Unknown | 31 976 (28.6%) | 27 253 (28.9%) | 542 (27.8%) | 4181 (27.2%) | |
| Sequence of treatment | |||||
| Primary cytoreduction | 47 661 (42.7%) | 40 250 (42.7%) | 804 (41.2%) | 6607 (42.9%) | 0.03 |
| Neoadjuvant chemotherapy | 13 127 (11.8%) | 10 985 (11.7%) | 247 (12.7%) | 1895 (12.3%) | |
| Unknown | 50 839 (45.5%) | 43 055 (45.7%) | 900 (46.1%) | 6884 (44.7%) | |
Baseline characteristics of the study patient included age, race, Spanish speaking, insurance, income, high school education, distance to care center, Charlson comorbidity score, year of diagnosis, grade, FIGO stage, days to treatment, days to surgery, residual disease, and sequence of treatment. Mean value of continuous features are displayed: age, days to treatment and to surgery, distance to tertiary level hospital. Data are numbers (%) unless stated otherwise.
FIGO, International Federation of Gynecology and Obstetrics.